Additionally, PIK3CA, AKT1, MAPK9, PRKCD, BRAF, IGF1R, and NOS3 were among the common target genes that were involved in reducing the severity of RA when different phytocannabinoids were used as treatment. This evidence concerns the gene MAPK9 and rheumatoid arthritis.